UW Virology Research Clinic
Welcome,         Profile    Billing    Logout  
 1 Trial 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Johnston, Christine
NCT04403139: VZV-specific Tissue Resident Memory T-cells After Shingrix Vaccination

Active, not recruiting
4
50
US
Shingrix
University of Washington, National Institute on Aging (NIA)
Varicella Zoster Virus Infection
02/26
02/26
NCT05908526: Insomnia Treatment and EMA (ecological Momentary Assessment) Outcomes

Completed
2
40
US
Baseline surveys, Cognitive testing and EMAs, ecological momentary assessment, Actiwatch, actigraphy, suvorexant (or placebo), Belsomra, Placebo, no drug
University of Maryland, Baltimore, Merck Sharp & Dohme LLC
Insomnia
08/24
08/24
NCT05298254 / 2021-003586-35: A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes

Active, not recruiting
1/2
505
Europe, Canada, US, RoW
Non-adjuvanted HSV formulation 1, Non-adjuvanted HSV formulation 2, Non-adjuvanted HSV formulation 3, HSV formulation 1 with adjuvant 1, HSV formulation 2 with adjuvant 1, HSV formulation 3 with adjuvant 1, HSV formulation 1 with adjuvant 2, HSV formulation 2 with adjuvant 2, HSV formulation 3 with adjuvant 2, Placebo, HSVTI_F1, HSVTI_F2
GlaxoSmithKline, GlaxoSmithKline Biologicals
Herpes Simplex
07/25
07/25
NCT06303778: Combining a Smartphone App With Medications to Manage Heavy Drinking

Not yet recruiting
N/A
330
US
Stand Down mobile app, Standard Care
VA Office of Research and Development
Alcohol Use Disorder (AUD)
11/28
11/28
Hauge, Kirsten
NCT05975060: A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.

Completed
2/3
660
US
XBB.1.5 Vaccine (Booster), Omicron sub variant XBB.1.5 vaccine( booster) SARS-CoV-2 rS /Matrix-M Adjuvant, XBB.1.5 Vaccine (single dose), Omicron sub variant XBB.1.5 vaccine(single dose) SARS-CoV-2 rS /Matrix-M Adjuvant
Novavax
COVID-19
11/23
05/24
Karita, Helen Stankiewicz
NCT04235257: Intradermal, Fractional Dose of HPV Vaccines:

Active, not recruiting
4
40
US
HPV vaccine
University of Washington
HPV Infection, HPV Vaccine
12/26
12/26
NCT05291871: Immunogenicity of Fractional Dose of the HPV Vaccines

Active, not recruiting
4
92
US
HPV vaccine
University of Washington
HPV Infection, HPV Vaccine
12/26
12/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Johnston, Christine
NCT04403139: VZV-specific Tissue Resident Memory T-cells After Shingrix Vaccination

Active, not recruiting
4
50
US
Shingrix
University of Washington, National Institute on Aging (NIA)
Varicella Zoster Virus Infection
02/26
02/26
NCT05908526: Insomnia Treatment and EMA (ecological Momentary Assessment) Outcomes

Completed
2
40
US
Baseline surveys, Cognitive testing and EMAs, ecological momentary assessment, Actiwatch, actigraphy, suvorexant (or placebo), Belsomra, Placebo, no drug
University of Maryland, Baltimore, Merck Sharp & Dohme LLC
Insomnia
08/24
08/24
NCT05298254 / 2021-003586-35: A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes

Active, not recruiting
1/2
505
Europe, Canada, US, RoW
Non-adjuvanted HSV formulation 1, Non-adjuvanted HSV formulation 2, Non-adjuvanted HSV formulation 3, HSV formulation 1 with adjuvant 1, HSV formulation 2 with adjuvant 1, HSV formulation 3 with adjuvant 1, HSV formulation 1 with adjuvant 2, HSV formulation 2 with adjuvant 2, HSV formulation 3 with adjuvant 2, Placebo, HSVTI_F1, HSVTI_F2
GlaxoSmithKline, GlaxoSmithKline Biologicals
Herpes Simplex
07/25
07/25
NCT06303778: Combining a Smartphone App With Medications to Manage Heavy Drinking

Not yet recruiting
N/A
330
US
Stand Down mobile app, Standard Care
VA Office of Research and Development
Alcohol Use Disorder (AUD)
11/28
11/28
Hauge, Kirsten
NCT05975060: A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.

Completed
2/3
660
US
XBB.1.5 Vaccine (Booster), Omicron sub variant XBB.1.5 vaccine( booster) SARS-CoV-2 rS /Matrix-M Adjuvant, XBB.1.5 Vaccine (single dose), Omicron sub variant XBB.1.5 vaccine(single dose) SARS-CoV-2 rS /Matrix-M Adjuvant
Novavax
COVID-19
11/23
05/24
Karita, Helen Stankiewicz
NCT04235257: Intradermal, Fractional Dose of HPV Vaccines:

Active, not recruiting
4
40
US
HPV vaccine
University of Washington
HPV Infection, HPV Vaccine
12/26
12/26
NCT05291871: Immunogenicity of Fractional Dose of the HPV Vaccines

Active, not recruiting
4
92
US
HPV vaccine
University of Washington
HPV Infection, HPV Vaccine
12/26
12/26

Download Options